News
Single-point mutations within the kinase domain of BCR–ABL constitute the most frequent cause of acquired resistance to ABL kinase inhibitors in patients with chronic myeloid leukaemia (CML ...
Cite this: Abl Tyrosine Kinase Inhibitors for Overriding Bcr-Abl/T315I: From the Second to Third Generation - Medscape - Sep 01, 2008.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback